Survival

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

By

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

By

The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

By

A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.

Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery

Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery

By

Two recent studies examined the benefits of using a 3D bioabsorbable marker to indicate the tumor bed in women with breast cancer who underwent breast conserving surgery (BCS).

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

By

An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.

Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients

Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients

By

Results from a sub-analysis of the impact of age on the safety and efficacy of lenvatinib in patients with RR-DTC in the SELECT trial showed that lenvatinib significantly increased PFS.

Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer

Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer

By

Regular use of NSAIDs after diagnosis of colorectal cancer correlated with improved survival in survivors with KRAS wild-type tumors.

Clinical Trials May Benefit Oncology Patients

Clinical Trials May Benefit Oncology Patients

By

Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

Survival Increased With First-Line Abiraterone-ADT Combination for Hormone-Naïve Prostate Cancer

By

Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.

Vaccine for Cervical Cancer Could Extend Survival in Relapsed Disease

Vaccine for Cervical Cancer Could Extend Survival in Relapsed Disease

Axalimogene filolisbac, an intravenous vaccine currently in clinical trials, could prevent often-fatal cervical cancer relapse.

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab

By

A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.

Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk

Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk

By

Whole genome sequencing of more than 3000 survivors of childhood cancers demonstrates the value of genetic testing for potential second cancers in this population.

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

Continuing Nivolumab After Progression of Head and Neck Cancer May Improve Survival

By

Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.

Annual Report Shows Decline in Cancer Death Rates, 1975-2014

Annual Report Shows Decline in Cancer Death Rates, 1975-2014

By

The joint report states that overall cancer rates have decreased for men, women, and children in all major race and ethnic groups. However, progress has been limited for some cancers.

Pembrolizumab May Help Combat Mesothelioma

Pembrolizumab May Help Combat Mesothelioma

By

Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.

SWOG Study Shows Robust, Longer Survival With Imatinib Therapy for GIST

SWOG Study Shows Robust, Longer Survival With Imatinib Therapy for GIST

By

A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

HMT Improves PFS in Serous Carcinoma of the Ovary, Peritoneum

By

Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.

SCLC: No Benefit from Pravastatin When Added to First-line Chemo

SCLC: No Benefit from Pravastatin When Added to First-line Chemo

By

The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer

By

Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

By

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

HNSCC Survival Worse for Patients in Lower Socioeconomic Population

HNSCC Survival Worse for Patients in Lower Socioeconomic Population

By

Investigators determined the impact of socioeconomic status on disease status at presentation and survival among patients with head and neck squamous cell carcinoma.

Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer

Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer

By

Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

By

There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.

Early Endometrial Cancer Surgery May Reduce Survival

Early Endometrial Cancer Surgery May Reduce Survival

By

The timing of surgery taking place following an endometrial cancer diagnosis may adversely impact survival.

Selumetinib + MK-2206 Fails to Improve Survival vs mFOLFOX in Pancreatic Cancer

Selumetinib + MK-2206 Fails to Improve Survival vs mFOLFOX in Pancreatic Cancer

By

Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.

Social Isolation Can Adversely Affect Breast Cancer Survival

Social Isolation Can Adversely Affect Breast Cancer Survival

Weak social ties are associated with poorer survival and a higher risk of breast cancer recurrence, researchers say.

Palliative Care Provides Benefits, But Does Not Extend Life for Patients With Cancer

Palliative Care Provides Benefits, But Does Not Extend Life for Patients With Cancer

By

A new meta-analysis examines the impact of palliative care services on patients' and caregivers' quality of life and outcomes.

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer

By

Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs